Evaxion A (EVAX) Notes Payables (2023 - 2025)

Evaxion A's (EVAX) quarterly Notes Payables came in at $1.1 million in Q2 2025, down 58.33% on a QoQ basis from $2.7 million in Q4 2023.

Evaxion A (EVAX) Notes Payables (2023 - 2025) Analysis & Trends

Evaxion A (EVAX) has 2 years of Notes Payables data on file, last reported at $1.1 million in Q2 2025.

Quarterly Notes Payables changed N/A year-over-year to $1.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $2.7 million, changed N/A from the prior year.
Notes Payables slipped to $1.1 million in Q2 2025, from $2.7 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $2.7 million in Q4 2023 to a low of $1.1 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Evaxion A	27.61 Mn	27.61 Mn	-

Download Data

Date	Value
Jun 30, 2025	1.13 Mn
Dec 31, 2023	2.71 Mn